As genetic testing for breast cancer gene mutation expands, questions arise about treatment decisions
- Written by: Katherine Drabiak, Assistant Professor of Bioethics and Genomics, University of South Florida
The Food and Drug Administration recently announced its authorization that permits genetics testing company 23andMe to market a test for gene mutations associated with risk of breast and ovarian cancer.
In response,...


